Imugene Limited
IMU.AX·ASX·Healthcare
0.0350+0.0050 (+16.67%)today
At close: Nov 5, 4:10 PM AEDT · May be delayed up to 20 min · AUD
Prices may be delayed up to 20 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Previous close0.0300
Open0.0300
Day range0.03000.0360
52-week range0.03000.4100
Off day high−2.78%
Off 52-week high−91.46%
Volume5.54M
Avg. volume (3M)2.72M
Market cap19.39M
EPS (TTM)-0.3200
Forward P/E-0.91
P/E ratio (TTM)—
Dividend yield—
Beta (5Y)2.38
Shares outstanding554.07M
Short interest—
Earnings dateJul 29, 2025 (est.)
Analyst target0.2300
Profit margin0.00%
Against its peers
Compare in full ›| IMU.AX | IMMP | GNLX | IMNN | BCTX | EVAX | |
|---|---|---|---|---|---|---|
| Market cap | 19.39M | 21.74M | 88.68M | 5.09M | 27.86M | 26.79M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -0.9 | -0.9 | -2.6 | -0.5 | -8.2 | -198.0 |
| Price/book | 1.6 | 0.5 | 5.4 | 2.2 | 1.7 | 2.6 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −91.04% | −91.38% | −63.02% | −77.02% | −70.55% | −47.70% |
| Today | +16.67% | −1.50% | +2.08% | +0.78% | +5.98% | +0.34% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 20 min.
Latest news
All IMU.AX news ›Imugene Reports New Responses With Azercabtagene Zapreleucel Plus BTK Inhibitor in Phase 1b Blood Cancer Trial
Imugene has reported one additional complete response in mantle cell lymphoma and one partial response in chronic lymphocytic leukemia in the BTK inhibitor combination cohort of its ongoing Phase 1b trial of azercabtagene zapreleucel…
From the 4Search news index, newest first.